Advertisement
Advertisement
U.S. Markets close in 6 hrs 26 mins
Advertisement
Advertisement
Advertisement
Advertisement

Immunic, Inc. (IMUX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.1485-0.0115 (-0.99%)
As of 09:33AM EST. Market open.
Advertisement

Immunic, Inc.

1200 Avenue of the Americas
Suite 200
New York, NY 10036
United States
332 255 9818
https://www.immunic-therapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees60

Key Executives

NameTitlePayExercisedYear Born
Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.AExec. Chairman426.62kN/A1971
Dr. Daniel VittCEO, Pres & Director621.67kN/A1968
Mr. Glenn Whaley CPAChief Financial Officer448.48kN/A1968
Dr. Andreas Muehler M.D., Ph.D.Chief Medical Officer538.19kN/A1964
Dr. Hella KohlhofChief Scientific OfficerN/AN/A1973
Jessica BreuHead of Investor Relations & CommunicationsN/AN/AN/A
Mr. Inderpal SinghGen. CounselN/AN/A1966
Mr. Patrick WalshChief Bus. OfficerN/AN/A1983
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Corporate Governance

Immunic, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement